10x Genomics Appoints Ansuman Satpathy, Joseph Gilliam to Board
Bitget2026/11/02 21:15- 10x Genomics appointed Ansuman Satpathy and Joseph Gilliam as Class III directors on October 28, 2026, effective immediately.
- Their terms run through the 2028 annual shareholder meeting.
- Gilliam was named chair of the board’s Audit Committee on October 30, 2026.
- Satpathy is a Stanford pathology and immunology associate professor, life sciences entrepreneur and former scientific adviser to the company.
- Gilliam is Glaukos’ president and chief operating officer, previously serving as its chief financial officer and a JPMorgan healthcare investment banking managing director.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays: Bloom Energy (BE.US) demand turning point is steeper than expected, rating raised to "Buy"
Barclays has upgraded Bloom Energy’s rating from "equal weight" to "overweight," setting a target price of $289.
Competitor turns supplier as the "new owner"! Bank of America: Marvell Technology's acquisition of Lumentum may prompt Cisco and Ciena to seek other sources
Bank of America analysts stated that Marvell Technology's acquisition of Lumentum may prompt Ciena and Cisco to diversify their optical component suppliers.
Goldman Sachs traders warn of an "invisible bear market": S&P 500 is only 3% away from its all-time high, but 60% of its constituent stocks have entered bear market territory.
The S&P 500 Index is only about 3% away from its latest record high, but 60% of the constituent stocks in this benchmark index are deeply entrenched in bear market territory.
Crypto prices
More
